RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty.
ACR 2022 Tweet by Dr. John Cush
TweetRelated Content
Podcast
Every day, every month, rheumatology publishes news and reports on JAK inhibitors, IL-17s, IL-23s, lupus, myositis, and scleroderma – all which could change how you practice dermatology. I'm Jack Cush from RheumNow, and This is Derm on RheumNow.
This month’s podcast will Scratch the surface and…
Podcast
On this weeks podcast Dr. Jack Cush reviews the news - Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age old messages for old age patients.
Reuters and the Wall Street Journal report that both Novartis and Bristol Myers Squibb (BMS) have paused their autoimmune disease CAR-T cell trials due to safety concerns, including deaths.Novartis has halted their cellular therapy trials with rap-cel (multiple autoimmune indications) because of 3…
